The missing part: the Archaeoglobus fulgidus Argonaute forms a functional heterodimer with an N-L1-L2 domain protein
Nucleic Acids Research · 2024
DOI: 10.1093/nar/gkad1241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2024. Verfasst von Elena Manakova und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio av. 7, LT-10257, Vilnius, Lithuania. Hauptthemen laut MEDLINE: Archaeoglobus fulgidus, Argonaute Proteins, Archaeal Proteins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Lithuania, Horizon 2020, Lithuanian Research Library Consortium LMBA.
Abstract (Originalsprache)
Argonaute (Ago) proteins are present in all three domains of life (bacteria, archaea and eukaryotes). They use small (15–30 nucleotides) oligonucleotide guides to bind complementary nucleic acid targets and are responsible for gene expression regulation, mobile genome element silencing, and defence against viruses or plasmids. According to their domain organization, Agos are divided into long and short Agos. Long Agos found in prokaryotes (long-A and long-B pAgos) and eukaryotes (eAgos) comprise four major functional domains (N, PAZ, MID and PIWI) and two structural linker domains L1 and L2. The majority (∼60%) of pAgos are short pAgos, containing only the MID and inactive PIWI domains. Here we focus on the prokaryotic Argonaute AfAgo from Archaeoglobus fulgidus DSM4304. Although phylogenetically classified as a long-B pAgo, AfAgo contains only MID and catalytically inactive PIWI domains, akin to short pAgos. We show that AfAgo forms a heterodimeric complex with a protein encoded upstream in the same operon, which is a structural equivalent of the N-L1-L2 domains of long pAgos. This complex, structurally equivalent to a long PAZ-less pAgo, outperforms standalone AfAgo in guide RNA-mediated target DNA binding. Our findings provide a missing piece to one of the first and the most studied pAgos.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio av. 7, LT-10257, Vilnius, Lithuania.
- Institute of Physics, Center for Physical Sciences and Technology, Savanoriu 231, LT-02300, Vilnius, Lithuania.
- Institute of Biochemistry, Life Sciences Center, Vilnius University, Sauletekio av. 7, LT-10257, Vilnius, Lithuania.
ORCID-Profile: Elena Manakova, Edvardas Golovinas, Reda Pocevičiūtė, Giedrius Sasnauskas, Arunas Silanskas, Danielis Rutkauskas, Marija Jankunec, Evelina Zagorskaitė, Edvinas Jurgelaitis, Algirdas Grybauskas, Česlovas Venclovas, Mindaugas Zaremba
Förderung
- Research Council of Lithuania
- Horizon 2020
- Lithuanian Research Library Consortium LMBA
- Cryo-EM
Zitieren
APA
Manakova, E., Golovinas, E., Pocevičiūtė, R., Sasnauskas, G., Silanskas, A., Rutkauskas, D., Jankunec, M., Zagorskaitė, E., Jurgelaitis, E., Grybauskas, A., Venclovas, Č., & Zaremba, M. (2024). The missing part: the Archaeoglobus fulgidus Argonaute forms a functional heterodimer with an N-L1-L2 domain protein. Nucleic Acids Research. https://doi.org/10.1093/nar/gkad1241
Vancouver
Manakova E, Golovinas E, Pocevičiūtė R, Sasnauskas G, Silanskas A, Rutkauskas D, et al. The missing part: the Archaeoglobus fulgidus Argonaute forms a functional heterodimer with an N-L1-L2 domain protein. Nucleic Acids Research. 2024. doi:10.1093/nar/gkad1241
BibTeX
@article{Manakova2024,
author = {Manakova, Elena and Golovinas, Edvardas and Pocevičiūtė, Reda and Sasnauskas, Giedrius and Silanskas, Arunas and Rutkauskas, Danielis and Jankunec, Marija and Zagorskaitė, Evelina and Jurgelaitis, Edvinas and Grybauskas, Algirdas and Venclovas, Česlovas and Zaremba, Mindaugas},
title = {The missing part: the Archaeoglobus fulgidus Argonaute forms a functional heterodimer with an N-L1-L2 domain protein},
journal = {Nucleic Acids Research},
year = {2024},
doi = {10.1093/nar/gkad1241}
}
EUVIMED